Summary
As part of International HEOR & PCO in International Value & Access, the Patient Centered Outcomes (PCO) HTA, TA Director within the HEOR TA teams, in partnership with HEOR leads co‑leads the PCO reimbursement strategy that enables measurements of patient centred outcomes to support robust payer value propositions and evidence for HTAs, optimizing international access for prioritized Novartis assets.
The PCO HTA TA Director will oversee one therapeutic area (e.g., CRM, immunology, oncology, or neurosciences) and their responsibility will span multiple assets/indications. The role includes supporting and guiding other members of the HEOR TA team for input or development of plans such as Health Technology Assessment Strategy Plans and Integrated Evidence Plans.
The PCO HTA TA Director will lead the HEOR Patient Centered Outcomes strategy within a Therapeutic Area and contribute to the OnePCO Strategy through direct interface with the Clinical Development PCO Center of Excellence when novel or disease‑specific PCOs are required.
In collaboration with regions and countries, the PCO HTA TA Director ensures that local PCO requirements are integrated into the PCO reimbursement strategy, global and international evidence plans, and PCO activities. Focus will be given to providing clear strategic rationale for the selection of health utility and other PROs for differentiation and translation to economic impact in partnership with HEOR. The Director also supports the implementation of country‑specific PCO evidence generation as needed to support access.
The Director, HEOR PCO, will serve as an internal expert on health utility assessment activities and lead health state valuation projects via time trade‑off or standard gamble studies where appropriate.
He/she supports HEOR TA on early scientific advice with HTAs (e.g., EU HTA JSC) and attends HTA meetings or supports negotiations in collaboration with cross‑functional and country team members. The Director cultivates strong partnerships with team members from internal groups including Access, Clinical Development, PCO COE, AQS Biostat, Medical Affairs, and the International Commercial organization.
The PCO HTA TA Director represents Novartis externally, ensuring thought leadership in collaboration with external partners (e.g., industry consortiums such as ISPOR, ISOQOL, PRO/Utility experts). Internally, the Director drives understanding of HTA requirements for PCO, health utility assessment, and adoption of standards and best practices.
Key Responsibilities
Co‑leads with the HEOR TA lead the development, delivery and communication of a compelling PCO reimbursement strategy within the HTAP, IPAS, 1BP, and aligned with Integrated Evidence Plan.
Works with the PCO COE, Global Program Teams, HEOR Leads, HTA Evidence Synthesis, Access, Medical Affairs, and AQS Biostat to ensure that the PCO measurement strategy includes patient‑reported outcomes and health utilities relevant for international HTAs and payers within the clinical development program.
Participates in and co‑leads projects on behalf of the OnePCO Alignment Forum to ensure PCOs critical for HTAs and payers are included in clinical trials, non‑interventional studies and real‑world studies for select assets and coordinates with countries to align on local HTA and payer needs.
Drives understanding of HTA requirements for PCO, health utility assessment, and adoption of standards and best practices by key markets.
Leads health state valuation projects via development and management of time trade‑off or standard gamble studies where appropriate.
Assists in scientific discussions with HTA agencies, particularly scientific advice from agencies such as EU HTA JSC, NICE, CADTH, for PRO/PCO endpoints, MCIDs, and by preparing appropriate briefing documents and dossiers to ensure a robust patient value proposition is included.
Develops strategic scientific communication plan including submission and presentation of research in peer‑reviewed journals and scientific/methodological congresses.
Engages with external thought leaders, identifies research collaboration or partnership opportunities, and represents Novartis with external stakeholders (academic institutions, HTA agencies) to monitor and shape the external environment with respect to patient‑centred outcomes research and evolving evidentiary standards for utility endpoints, ensuring awareness of these changes for Novartis.
Leads above‑brand research projects or initiatives to pilot innovative methodologies for value demonstration and elevate internal standards and best practices within International Value and Access and at Novartis with cross‑functional partners.
Essential Requirements
8+ years of Pharma Industry experience with 5+ years in HEOR roles in pharmaceutical companies or consulting, with at least 3 years demonstrating specific leadership of health utility projects.
Advanced Degree in a relevant field.
Experience in evaluating, developing and validating PRO/PCO instruments to meet HTA reimbursement requirements.
In-depth understanding of key patient‑centred outcomes measurement systems – e.g., EuroQoL, Quality Metric Short‑Form measures, HUI, etc.
Ability to lead in a cross‑functional environment.
Ability to manage multiple priorities in a rapidly changing environment.
Ability to work collaboratively to leverage other HEOR capabilities (strategy, regions, countries, COE PCO).
Desirable Requirements
Ph.D., M.D., MBA, MSc or equivalent. Strong external interfaces and network: KOLs, clinical research and scientific group, payers, and policy organizations.
Experience in conducting and evaluating PCO measures from conceptualization through negotiation with international health authorities. Experience in HTA submissions.
Location
This role can be based in the UK, London, but also in Dublin, Ireland or Basel, Switzerland.
Benefits
Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: Novartis Life Handbook.
Commitment to Diversity & Inclusion
Novartis is committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve.
Why Novartis
Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture
Benefits and Rewards
Learn about all the ways we’ll help you thrive personally and professionally.
#J-18808-Ljbffr